IDEAYA Biosciences Q1 2025 Earnings Report

IDEAYA Biosciences EPS Results

• Actual EPS: -$0.82
• Consensus EPS: -$0.75
• Beat/Miss: Missed by -$0.07
• One Year Ago EPS: -$0.53

IDEAYA Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.10 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

IDEAYA Biosciences Announcement Details

• Quarter: Q1 2025
• Date: 5/6/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 6, 2025
• Conference Call Time: 6:00AM ET

IDEAYA Biosciences (NASDAQ:IDYA) is a publicly traded clinical-stage precision oncology company focused on synthetic lethality as a novel therapeutic approach for the treatment of genetically defined cancers. The company leverages its proprietary knowledge of DNA damage response and repair pathways to design small‐molecule inhibitors that selectively target tumor cells harboring specific genetic alterations. By exploiting vulnerabilities in cancer cell survival mechanisms, IDEAYA aims to develop differentiated therapies with improved efficacy and tolerability profiles.

The company’s pipeline includes multiple small‐molecule programs addressing key oncology targets. IDEAYA’s lead synthetic lethality candidates are designed to inhibit enzymes involved in DNA replication and repair, with the goal of inducing tumor-specific cell death in cancers with loss‐of‐function mutations or epigenetic alterations. In addition to its in‐house discovery efforts, IDEAYA has established collaborations with leading global biopharmaceutical companies to expand its synthetic lethality platform and accelerate clinical development.

Since its founding in 2016 and subsequent initial public offering in 2019, IDEAYA has cultivated partnerships with major industry players including Servier and GSK to co‐develop targeted therapies and share research insights. These alliances support IDEAYA’s goal of advancing multiple programs into later-stage clinical trials while retaining the flexibility to pursue new synthetic lethality targets through its integrated discovery engine.

Headquartered in South San Francisco, California, IDEAYA Biosciences operates research and development activities in the United States and collaborates with international academic and clinical centers. The company is led by an experienced management team with deep expertise in oncology drug discovery and development, positioning IDEAYA to deliver innovative, biomarker-driven therapies to patients with high unmet medical needs.